Hospital-acquired pneumonia: Coverage and treatment adequacy of current guidelines

European Respiratory Journal

Volumn 22, Issue 6, 2003, Pages 876-882

  Ioanas, M ^a   Cavalcanti, M ^b   Ferrer, M ^b   Valencia, M ^b   Agusti, C ^b   Puig de la Bellacasa, J ^b   Torres, A ^b  

^a MDR TB Centre   (Romania)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Guidelines; Hospital acquired pneumonia; Treatment adequacy

Indexed keywords

ACICLOVIR; AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN; ANTIBIOTIC AGENT; AZTREONAM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; FLUCONAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; METICILLIN; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TOBRAMYCIN; TUBERCULOSTATIC AGENT; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DRUG EFFICACY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA OXYTOCA; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; STATISTICAL ANALYSIS; STENOTROPHOMONAS MALTOPHILIA; TREATMENT FAILURE; TREATMENT OUTCOME; URINALYSIS;

AGED; BACTERIA; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PNEUMONIA; PRACTICE GUIDELINES; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0346121626     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.03.00045903     Document Type: Article

References (28)

1. American Thoracic Society. Hospital acquired-pneumonia in adults: diagnosis assessment, initial therapy and prevention - a consensus statement. Am J Respir Crit Care Med 1996; 153: 1711-1725.
2. Trouillet JL, Chastre J, Vuagnat A, et al. Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157: 531-539.
3. Alvarez-Lerma F, and the ICU Study Group. Modification of the empiric treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 1996; 22: 387-394.
4. Kollef MH, Fraser VJ. Antibiotic resistance in intensive care unit. Ann Intern Med 2001; 134: 298-314.
5. Crouch Brewer S, Jones CB, Leeper KV, Wunderink RG. Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996; 109: 1029.
6. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111: 685.
7. Ioanas M, Ferrer R, Angrill A, Ferrer M, Torres A. Microbial investigation in ventilator-associated pneumonia. Eur Respir J 2001; 17: 791-801.
8. Leroy O, Giradie P, Yazdanpanah Y, et al. Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens. Eur Respir J 2002; 20: 432-439.
9. Johanson WG Jr, Pierce AK, Sanford JP, Thomas GD. Nosocomial respiratory infections with Gram-negative bacilli: the significance of colonization of the respiratory tract. Ann Intern Med 1972; 77: 701-706.
10. Ruiz M, Torres A, Ewig S, et al. Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia. Evaluation of outcome. Am J Respir Crit Care Med 2000; 162:119-125.
11. Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE. APACHE: acute physiology and chronic health evaluation - a physiologically based classification system. Crit Care Med 1981; 9: 591-597.
12. Sanchez-Nieto AM, Torres A, Garcia-Cordoba A, et al. Impact of invasive and non-invasive quantitative culture sampling of ventilator-associated pneumonia. Am J Respir Crit Care Med 1998; 157: 371-376.
13. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections. A risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-474.
14. Iregui M, Ward S, Sherman G, Fraser V, Kollef M. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122: 262-268.
15. Grusson D, Hilbert G, Vargas F, et al. Rotation and restricted use of antibiotics in a medical intensive care unit. Am J Respir Crit Care Med 2000; 162: 837-843.
16. Kollef MH, Ward S, Sherman G. Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. Crit Care Med 2000; 28: 3456-3464.
17. Dupont H, Mentec H, Sollet JP, Bleichner G. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001; 27: 355-362.
18. Rello J, Sa-Borges M, Correa H, Leal SR, Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites. Am J Respir Crit Care Med 1999; 160: 608-613.
19. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am J Respir Crit Care Med 2001; 163: 1730-1754.
20. National Nosocomial Infections Surveillance (NNIS) System. National Nosocomial Infections Surveillance System report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999; 27: 520-532.
21. Fagon JY, Chastre J, Comart Y, Trouillet JL, Gilbert C. Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis 1996; 23: 538-542.
22. Hanberger H, Garcia-Rodriguez JA, Bobernado M, Goossens H, Nilsson LE, Struelens MJ. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. JAMA 1999; 281: 67-71.
23. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165: 867-902.
24. Naimi TS, LeDell KH, Boxrud DJ, Groom AV, Steward CD. Epidemiology and clonality of community-acquired MRSA in Minnesota, 1996-1998. Clin Infect Dis 2001; 33: 990-996.
25. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29: 1109-1115.
26. Betriu C, Sanchez A, Palau ML, Gomez M, Picazo IL. Antibiotic resistance surveillance of Stenotrophomonas maltophilia. 1993-1999. J Antimicrob Chemother 2001; 48: 152-154.
27. Hanes SD, Demirkan K, Tolley E, et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 2002; 35: 228-235.
28. Dean NC, Silver MP, Bateman KA, James B, Hadlock CJ, Hale D. Decrease mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 2001; 110: 451-457.